NCT07444710 2026-03-18
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Medical College of Wisconsin
First Affiliated Hospital of Zhejiang University
Navy General Hospital, Beijing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Ruijin Hospital
The First Affiliated Hospital with Nanjing Medical University